Atlas Venture’s Post

🔬 Following on from our poll a couple of weeks ago, we're bringing you a deeper dive into the topic of oncology drugs! 🧪 Did you know that less than 1% of the oncology drugs in pre-clinical development make it to market? Hence why the work of companies like Onward Therapeutics is so important! Armand de Gramont, co-founder and CSO of Onward Therapeutics, spoke to us for our June newsletter: he described how his company fast-tracks promising cancer treatments to the clinic, with the aim of giving patients more options in the fight against this disease. 👉 Check out the full article here: https://lnkd.in/gpdyR4bS

Meet our Chief Scientific Officer, Dr. David Tice. With over 20 years of biopharmaceutical research and drug development experience in oncology, Dr. Tice has led research of multiple therapeutic modalities across many types of cancer. Learn about Dr. Tice’s perspective on the evolution of immunotherapy over the years and how cell therapy is advancing cancer care.

While great strides have been made in diagnosing and treating #breastcancer, there remains an unmet need for additional effective treatment options. #BreastCancerAwarenessMonth is about more than just raising awareness, it’s about taking action. At ORIC, #breastcancer is a key area of focus. We are developing our EGFR/HER2 inhibitor ORIC-114, and our PLK4 inhibitor as potential treatments for breast cancer. Learn more here: https://bit.ly/3ARUtUR #BCAM 

Discover what HCPs are saying about the future of #Oncology treatments. Our research highlights six emerging #cancer drugs that #HCPs have shared their opinions about online: - Immunotherapies - Targeted therapies - CAR-T cell therapies - Antibody-drug conjugates - Vaccines for cancer - Radiopharmaceutical therapies Download our whitepaper for in-depth insights into HCP perspectives on the future of Oncology. #ASCO24 https://lnkd.in/et3Fcsmh

How can we inspire adoption of innovative cancer diagnostics? Communication between industry, pharmaceutical companies, oncologists, and pathologists is key to ensuring rapid tumour diagnosis in breast cancer. And use of MammaTyper® is a way to enable innovation. As Dr Dario DeBiase says, MammaTyper® means you can continue to work well, whilst adding in “another tool to help you provide more reliable results.”  #BreastCancerDiagnosis #CancerInnovation

Unlocking new vaccine adjuvants and delivery systems has been a game-changer in advancing oncology drug development. The research and developments in this field are promising and offer hope for more effective cancer therapies. Discover more about these exciting breakthroughs in the new article by Pharma insights! Click here to read: https://ow.ly/m2sx30sEqib #CrodaPharma #EmpoweringBiologicsDelivery #PharmaInsights

From a rising number of randomized trials to utilizing biomarker endpoints, oncology programs have become increasingly complex. Find out the latest trends in oncology trial design from our blog https://ow.ly/I1Tv50QkEjn

Unlocking new vaccine adjuvants and delivery systems has been a game-changer in advancing oncology drug development. The research and developments in this field are promising and offer hope for more effective cancer therapies. Discover more about these exciting breakthroughs in the new article by Pharma insights! Click here to read: https://ow.ly/9UTj30sEogf #CrodaPharma #EmpoweringBiologicsDelivery #PharmaInsights

Unlocking new vaccine adjuvants and delivery systems has been a game-changer in advancing oncology drug development. The research and developments in this field are promising and offer hope for more effective cancer therapies. Discover more about these exciting breakthroughs in the new article by Pharma insights! Click here to read: https://ow.ly/Oum430sEysY #CrodaPharma #EmpoweringBiologicsDelivery #PharmaInsights